The Role of IGF-1R in Pediatric Malignancies

被引：80

作者：

Kim, Su Young ^{[1
]}

Toretsky, Jeffrey A. ^{[2
]}

Scher, Daniel ^{[2
]}

Helman, Lee J. ^{[1
]}

机构：

[1] NCI, Ctr Canc Res, Pediat Oncol Branch, NIH, Bethesda, MD 20892 USA

[2] Georgetown Univ, Sch Med, Lombardi Comprehens Canc Ctr, Washington, DC USA

来源：

ONCOLOGIST | 2009年 / 14卷 / 01期

关键词：

IGF-1R; Pediatric malignancy; Molecular targeting; Therapeutic antibody; GROWTH-FACTOR-I; AUTOCRINE GROWTH; EWINGS-SARCOMA; WILMS-TUMOR; FACTOR RECEPTOR; MONOCLONAL-ANTIBODIES; SIGNAL-TRANSDUCTION; ANTITUMOR-ACTIVITY; INSULIN; EXPRESSION;

D O I：

10.1634/theoncologist.2008-0189

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The insulin-like growth factor (IGF) family consists of ligands (IGF-I, IGF-II, insulin), several receptors (including IGF-1R), and six binding proteins (IGFBP-1 through IGFBP-6). Members of this family regulate key cellular activities and they also play an important role in the development and progression of both adult and childhood cancers. Binding of a ligand to the receptor leads to its activation, followed by signal transduction along several pathways. In some childhood malignancies, IGF-1R can be activated by endocrine, autocrine, or paracrine mechanisms. Although mutations in IGF-1R have not been identified, this signaling pathway is upregulated in many childhood cancers. These findings have led to the development of a host of IGF-1R signaling modulators that are currently being tested in clinical trials. This review explores the role of IGF-1R in a range of childhood malignancies. The Oncologist 2009; 14: 83-91

引用

页码：83 / 91

页数：9

共 72 条

[61] The insulin-like growth factor-I receptor is required for EWS/FLI-1 transformation of fibroblasts [J].

Toretsky, JA ;

Kalebic, T ;

Blakesley, V ;

LeRoith, D ;

Helman, LJ .

JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (49) :30822-30827

[62]

Toretsky JA, 2001, CANCER-AM CANCER SOC, V92, P2941, DOI 10.1002/1097-0142(20011201)92:11<2941::AID-CNCR10072>3.0.CO

[63]

2-C

[64] Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism [J].

Wan, X. ;

Harkavy, B. ;

Shen, N. ;

Grohar, P. ;

Helman, L. J. .

ONCOGENE, 2007, 26 (13) :1932-1940

[65]

WERNER H, 1995, MOL CELL BIOL, V15, P3516

[66] INCREASED EXPRESSION OF THE INSULIN-LIKE GROWTH FACTOR-I RECEPTOR GENE, IGF1R, IN WILMS-TUMOR IS CORRELATED WITH MODULATION OF IGF1R PROMOTER ACTIVITY BY THE WT1 WILMS-TUMOR GENE-PRODUCT [J].

WERNER, H ;

RE, GG ;

DRUMMOND, IA ;

SUKHATME, VP ;

RAUSCHER, FJ ;

SENS, DA ;

GARVIN, AJ ;

LEROITH, D ;

ROBERTS, CT .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (12) :5828-5832

[67] The role of circulating IGF-1 - Lessons from human and animal models [J].

Yakar, S ;

Wu, YP ;

Setser, J ;

Rosen, CJ .

ENDOCRINE, 2002, 19 (03) :239-248

[68] INSULIN-LIKE GROWTH FACTOR-I EXPRESSION BY TUMORS OF NEUROECTODERMAL ORIGIN WITH THE T(11-22) CHROMOSOMAL TRANSLOCATION - A POTENTIAL AUTOCRINE GROWTH-FACTOR [J].

YEE, D ;

FAVONI, RE ;

LEBOVIC, GS ;

LOMBANA, F ;

POWELL, DR ;

REYNOLDS, CP ;

ROSEN, N .

JOURNAL OF CLINICAL INVESTIGATION, 1990, 86 (06) :1806-1814

[69] Clinical pharmacodynamic effects of the growth hormone receptor antagonist pegvisomant: Implications for cancer therapy [J].

Yin, Donghua ;

Vreeland, Franzanne ;

Schaaf, Larry J. ;

Millham, Robert ;

Duncan, Barbara A. ;

Sharma, Amarnath .

CLINICAL CANCER RESEARCH, 2007, 13 (03) :1000-1009

[70]

YUN K, 1993, LAB INVEST, V69, P603

← 1 2 3 4 5 6 7 8 →